PMV PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
PMV PHARMACEUTICALS, INC. (PMVP) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $0.00 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-14
- PMV PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.53.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $3.29, a 155.04% increase year-over-year.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2022-03-31 was $1.29, a 17.83% decline year-over-year.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $1.29, a 126.32% increase from fiscal 2024.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $0.57, a 3.39% decline from fiscal 2023.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $0.59, a 64.67% decline from fiscal 2022.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $1.67, a 17.73% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $1.29 10-K · filed 2026-03-06 | |||
| 2025-09-30 | $0.53 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $0.53 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $0.53 10-Q · filed 2025-05-09 | |||
| 2024-12-31 | $0.57 10-K · filed 2025-03-03 | |||
| 2024-09-30 | $1.80 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $1.80 10-Q · filed 2024-08-08 | |||
| 2023-12-31 | $0.59 10-K · filed 2024-02-29 | |||
| 2023-09-30 | $0.73 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $2.55 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | $3.29 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | $1.67 10-K · filed 2023-03-01 | |||
| 2022-09-30 | $1.08 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $1.06 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $1.29 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $2.03 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $2.17 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | $2.15 10-Q · filed 2021-08-13 | |||
| 2021-03-31 | $1.57 10-Q · filed 2021-05-14 | |||
| 2020-12-31 | $1.59 10-K · filed 2021-03-03 | |||
| 2019-12-31 | $3.00 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |